Laura Panjwani

Breast cancer specialist Mark Pegram discusses recent breast cancer studies and what's to come for patients with HER2-positive breast cancer.

Investigational monoclonal antibodies, such as daratumumab and elotuzumab, could potentially change the role of stem cell transplantation for patients with multiple myeloma.

With a growing number of people turning to social media for medical advice, it appears to be more important than ever for physicians to be contributing to the conversation.

The addition of Perjeta (pertuzumab) to Herceptin (trastuzumab) and docetaxel as a first-line therapy for metastatic HER2-positive breast cancer improved overall survival (OS) by nearly 16 months, according to findings from the phase 3 CLEOPATRA study.

Richard Finn, of the Jonsson Comprehensive Cancer Center at UCLA and lead investigator of the PALOMA-1 study, explains the clinical implications of Ibrance's approval for hormone-positive, HER2-negative metastatic breast cancer.

On the evolving role of PARP inhibitors in the treatment of ovarian cancer, Donna McNamara, co-chief of Gynecological Oncology at the John Theurer Cancer Center (JTCC), discusses the impact of these studies and the outlook going forward.

Changing the administration schedule for Gemzar (gemcitabine) plus Abraxane (nab-paclitaxel) from weekly to every other week significantly reduced side effects without impacting efficacy as a frontline treatment for patients with metastatic pancreatic cancer, according to a retrospective study presented at the 2015 GI Cancers Symposium.

A "watch and wait" surveillance approach may allow certain patients with rectal cancer to achieve excellent outcomes without immediate surgery, according to a retrospective review of clinical data presented at the 2015 Gastrointestinal Cancers Symposium.